How can the potential of the duocarmycins be unlocked for cancer therapy?
Publication date
2021-02Keyword
DuocarmycinsCancer therapy
Therapeutic agents
Prodrug approaches
Antibody-directed technologies
Peer-Reviewed
YesOpen Access status
closedAccess
Metadata
Show full item recordAbstract
The duocarmycins belong to a class of agent that has fascinated scientists for over four decades. Their exquisite potency, unique mechanism of action, and efficacy in multidrug-resistant tumour models makes them attractive to medicinal chemists and drug hunters. However, despite great advances in fine-tuning biological activity through structure-activity relationship studies (SARS), no duocarmycin-based therapeutic has reached clinical approval. In this review, we provide an overview of the most promising strategies currently used and include both tumour-targeted prodrug approaches and antibody-directed technologies.Version
No full-text in the repositoryCitation
Jukes Z, Ribeiro Morais G, Loadman PM et al (2021) How can the potential of the duocarmycins be unlocked for cancer therapy? Drug Discovery Today. 26(2): 577-584.Link to Version of Record
https://doi.org/10.1016/j.drudis.2020.11.020Type
Articleae974a485f413a2113503eed53cd6c53
https://doi.org/10.1016/j.drudis.2020.11.020